Cure8 research brief
For people with UC on long-term tofacitinib, this trial provides evidence about the chances of keeping remission after stepping down dose and about safety differences between 10 mg and 5 mg twice daily over 30 months.
Adults with ulcerative colitis on tofacitinib, clinicians managing maintenance therapy, and researchers interested in long-term dosing strategies and safety of JAK inhibitors.
The randomized trial enrolled adults in stable, corticosteroid-free remission on tofacitinib 10 mg BID for at least 2 years and followed them for 30 months after randomization to either continue 10 mg or reduce to 5 mg BID.
At month 30 about half of patients randomized to 5 mg BID and about 63% randomized to remain on 10 mg BID maintained modified Mayo score remission. Patients with endoscopic subscore 0 at baseline and those without prior TNFi failure were more likely to stay in remission after dose reduction.
Most patients who relapsed after reduction and were escalated back to 10 mg recaptured remission. Safety points: serious infections and herpes zoster events were reported more often with the 10 mg dose than with 5 mg, consistent with the known tofacitinib safety profile. Overall adverse event rates were similar between doses.
This abstract summarizes trial results and does not provide full patient-level data or prespecified subgroup statistics in this text. Clinical decisions about dose changes should be made with a treating clinician, considering individual risks and benefits.
This entry is based on the article abstract (RIVETING, NCT03281304) published in Crohn's & Colitis 360; the content depth is an abstract. The full paper would be needed to review detailed methods, subgroup definitions, and statistical analyses. The numbers reported here are from the abstract only.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study suggests tofacitinib may work quickly as a rescue option for biologic‑naive patients with steroid‑refractory ASUC and that many achieved steroid‑free remission by 24 weeks — information that could matter when...
A Phase 3 study is testing whether oral tofacitinib can induce and maintain remission in children with moderate-to-severe ulcerative colitis — a key step before pediatric regulatory approvals and wider clinical use.
Patients and clinicians considering sequencing of advanced UC therapies may care because this study reports differences in how long patients stayed on second-line treatment depending on the order of anti-TNF agents and...
